Caroline Zangani

[NIHR Applied Research Collaborations (ARCs) @NIHRARCs]

#ARCadvent day 2⃣0⃣:
Research led by @UniofOxford & supported by @arc_oxtv reveals stimulants & atomoxetine as the most effective treatments for managing Attention Deficit Hyperactivity Disorder #ADHD in adults, based on an analysis of 113 clinical trials. https://t.co/jua3QFg7tC

[Samuele Cortese @CorteseSamuele]

What are the best treatments for adults with #ADHD? Answer in our study in The Lancet Psychiatry

https://t.co/ipQtG9fnx9

@EGOstinelli @And_Cipriani @CarolineZangani @CinziaGiovane @UK_ADHD et al

[Samuele Cortese @CorteseSamuele]

Our study, funded by the @NIHRresearch and led by the amazing @EGOstinelli, with @And_Cipriani and many other colleagues, in The Lancet Psychiatry. The most comprehensive evidence synthesis of RCTs of pharmacological and non-pharmacological treatments for adult #ADHD

[Edoardo G. Ostinelli @EGOstinelli]

1/ 📢 New research: we’ve conducted the most comprehensive analysis of treatments for ADHD in adults, including pharmacological, psychological, and neurostimulation approaches. Here’s what we found — and what it means for treatment decisions. 🧵 https://t.co/CMRkciDBqD

[The Mental Elf @Mental_Elf]

Drawing the morning to a close, this is Hannah @Macfarlanes25 sharing from a session by Edoardo Ostinelli @EGOstinelli: Personalisation of Pharmacological Treatments in Depression: The Role of Shared Decision-Making @OxfordPPL @CMHPCommunity #cmhp24

THREAD 🧵

[Caroline Zangani @CarolineZangani]

Well done - very important paper! @And_Cipriani @EGOstinelli #migraine #systematicreview

[Oxford Psychiatry @OxPsychiatry]

📢NEW PAPER
Triptans, a drug usually offered as an alternative to painkillers, have been found to be the most effective medicine for adults who experience acute migraines.

Research @And_Cipriani @OxfordPPL published @bmj_latest 👇

https://t.co/GBWqZ9qqdJ
@OxfordMedSci @OxNeuro

[Oxford Psychiatry @OxPsychiatry]

📢NEW PAPER
Triptans, a drug usually offered as an alternative to painkillers, have been found to be the most effective medicine for adults who experience acute migraines.

Research @And_Cipriani @OxfordPPL published @bmj_latest 👇

https://t.co/GBWqZ9qqdJ
@OxfordMedSci @OxNeuro

[Oxford Health NHS FT @OxfordHealthNHS]

The ABATE Study is about #Alzheimers disease in people with Down syndrome. It is testing whether a potential treatment can slow down memory and thinking problems.
Contact us: [email protected], or visit https://t.co/D3V5Ioosdd

[Andrea Cipriani @And_Cipriani]

Come to @UniofOxford for the 9th Course on Network Meta-Analysis, 17-19 June 2024. The course is aimed at clinicians, researchers and policy makers in the health care field, but it is open to everybody. Places still available, please book here: https://t.co/IvfE3EEJNx

[Oxford Psychiatry @OxPsychiatry]

People with #depression are being invited to be part of a major clinical trial testing a new AI treatment tool to personalise antidepressant treatment.

If you are interested in being part of the PETRUSHKA trial, see below 👇

https://t.co/TfcD89uJfA

#MentalHealthAwarenessWeek

[BMJ Mental Health @BMJMentalHealth]

Looking ahead to 2024.
Hear directly from our Editor-in-Chief @And_Cipriani as they share invaluable advice on the year ahead. Find out more at: https://t.co/GXsGHoz4Rp #bmjeditors #bmjpublishingtips #bmjjournalinsights

[John Torous, MD MBI @JohnTorousMD]

Blending perspectives of service users, clinicians, researchers, funders, and more - this editorial highlights how innovation in digital health for #schizophrenia offers leading examples of rigor, patient/public involvement, and clinical integration:
https://t.co/3n3Lx8RpxQ

[OxfordPPL @OxfordPPL]

The PETRUSHKA Trial is open to recruitment and aims to personalise treatment for adults with depression. Find out if you are eligible by completing our short screening form today: https://t.co/ng5mWxK8QU
#ResearchTransformsLives #BePartofResearch #NIHR #OxPPL

[Susie Murphy @SusieMurphy]

Job alert! We have a Research Assistant position available in @OxfordPERL Please re-tweet and flag to anyone who might be interested. https://t.co/68drtLNLG4

[GALENOS @GALENOS_Global]

The 1st GALENOS open protocol has been published on @WellcomeOpenRes, only 20 days after submission!

Trace amine-associated receptor 1 (TAAR1) agonists for psychosis: protocol for a living systematic review and meta-analysis of human & non-human studies. https://t.co/f8PlkPUZgn

[Andrea Cipriani @And_Cipriani]

We're looking for a new Band 5 Clinical Research Practitioner/Research Assistant at @OxfordHealthNHS Clinical Research Facility @NIHRresearch. Details here: https://t.co/cTfgXXtc0F
And on the #NHS Jobs site here: https://t.co/ZS0uZ03NjJ. The closing date is 17-Sep-2023.

[Edoardo G. Ostinelli @EGOstinelli]

⚡️So many people already joined our study! We are exploring how to communicate ✅ benefits and ⚠️ harms of medical interventions.

Aged between 18 and 65? This online study takes only 20 minutes to complete! 🫵 #MedTwitter #healthcare #medicine #PatientCare #patientsafety

🧵⬇️

[Andrea Cipriani @And_Cipriani]

Join our 7th Systematic Review Course @UniofOxford: 4th-6th Oct 2023. It's online & open to anyone interested in evidence synthesis & evidence-based practice. Specifically designed for people interested in Brain Health @OxfordPPL @OxPsychiatry @OxHealthBRC https://t.co/Xi3uGIH4Nd

[Andrea Cipriani @And_Cipriani]

GALENOS aims to understand the mechanisms behind what works and what doesn’t work about pharmacological & non-pharmacological treatments, diagnosis & prognostic tools in depression, anxiety & psychosis. https://t.co/z5fQ1NEZAW @WellcomeOpenRes @UniofOxford https://t.co/PcOQQSjxuh